日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Primary endpoint acceptance is strongly associated with a positive benefit assessment: a self-fulfilling prophecy

主要终点接受度与积极的获益评估密切相关：一种自我实现的预言

期刊:Lancet Regional Health-Europe
影响因子:
doi:10.1016/j.lanepe.2025.101577
Dintsios, Charalabos-Markos
发表日期：2026
文献求助 收藏

Prevalence, Incidence, and Risk of Different Comorbidity Categories in Pediatric Multiple Sclerosis: A Systematic Review and Meta-Analysis Protocol

儿童多发性硬化症不同合并症类别的患病率、发病率和风险：系统评价和荟萃分析方案

期刊:Children-Basel
影响因子:
doi:10.3390/children13020307
Samadzadeh, Sara; Mirzai, Moein; Qanati, Aysan Valinejad; Icks, Andrea; Dintsios, Charalabos-Markos
神经科学
多发性硬化症
发表日期：2026
文献求助 收藏

How do patients with primary hypertension assess different endpoints of their treatment? a survey using analytic hierarchy process

原发性高血压患者如何评估其治疗的不同终点？一项采用层次分析法的调查

期刊:Journal of Human Hypertension
影响因子:
doi:10.1038/s41371-026-01135-8
Dintsios, Charalabos-Markos; Chernyak, Nadezda
心血管
高血压
发表日期：2026
文献求助 收藏

Acceptance of Evidence Transfer Within German Early Benefit Assessment of New Drugs for Pediatric and Adolescents Target Populations

德国对儿科和青少年目标人群新药早期获益评估中证据转移的接受度

期刊:Pharmacoeconomics
影响因子:4.6
doi:10.1007/s40273-024-01467-8
Pick, Georgia; Müller, Dirk; Dintsios, Charalabos-Markos
发表日期：2025
文献求助 收藏

Letter to the Editor Regarding "Indirect Treatment Comparisons in Healthcare Decision Making: A Targeted Review of Regulatory Approval, Reimbursement, and Pricing Recommendations Globally for Oncology Drugs in 2021-2023"

致编辑的信，主题为“医疗保健决策中的间接治疗比较：2021-2023年全球肿瘤药物监管审批、报销和定价建议的重点审查”

期刊:Advances in Therapy
影响因子:4
doi:10.1007/s12325-025-03269-6
Tomeczkowski, Jörg; Leverkus, Friedhelm; Bussilliat, Paul; Osowski, Ulrike; Herrmann, Kirsten H; Eichinger, Birte; Heidbrede, Tanja; Schmitter, Sarah; Dietrich, Eva Susanne; Dintsios, Charalabos-Markos; Bluhmki, Tobias
肿瘤
肿瘤免疫
发表日期：2025
文献求助 收藏

Cost-Effectiveness of Family Conferences to Reduce Polypharmacy in Frail Older Adults

家庭会议在减少体弱老年人多重用药方面的成本效益

期刊:
影响因子:
doi:10.1111/jgs.19606
Montalbo, Joseph; Dintsios, Charalabos-Markos; Abraham, Jens; Drewelow, Eva; Ritzke, Manuela; Mortsiefer, Achim; Wiese, Birgitt; Thürmann, Petra; Wilm, Stefan; Icks, Andrea
发表日期：2025
文献求助 收藏

National health and economic impact of a lifestyle program to prevent type 2 diabetes mellitus in Germany: a simulation study

德国一项旨在预防2型糖尿病的生活方式干预项目对国民健康和经济的影响：一项模拟研究

期刊:Bmj Open Diabetes Research & Care
影响因子:4.1
doi:10.1136/bmjdrc-2024-004382
Ogurtsova, Katherine; Laxy, Michael; Emmert-Fees, Karl; Dintsios, Charalabos-Markos; Zhang, Ping; Icks, Andrea
糖尿病
代谢
发表日期：2024
文献求助 收藏

Cost-effectiveness of incentives for physical activity in coronary heart disease in Germany: pre-trial health economic model of a complex intervention following the new MRC framework

德国冠心病患者体育锻炼激励措施的成本效益分析：基于新MRC框架的复杂干预措施的试验前卫生经济学模型

期刊:BMJ Open Sport & Exercise Medicine
影响因子:3.2
doi:10.1136/bmjsem-2024-001896
Mohebbi, Damon; Ogurtsova, Katherine; Dyczmons, Jan; Dintsios, Markos; Kairies-Schwarz, Nadja; Jung, Christian; Icks, Andrea
心血管
冠心病
发表日期：2024
文献求助 收藏

How Far is Germany From Value-Based Pricing 10 Years After the Introduction of AMNOG?

AMNOG实施10年后，德国距离实现基于价值的定价还有多远？

期刊:Applied Health Economics and Health Policy
影响因子:3.3
doi:10.1007/s40258-021-00712-x
Dintsios, Charalabos-Markos; Chernyak, Nadja
发表日期：2022
文献求助 收藏

The impact of additive or substitutive clinical study design on the negotiated reimbursement for oncology pharmaceuticals after early benefit assessment in Germany

德国早期获益评估后，附加或替代性临床研究设计对肿瘤药物协商报销的影响

期刊:Health Economics Review
影响因子:3.3
doi:10.1186/s13561-020-00263-2
Dintsios, C M; Beinhauer, I
肿瘤
肿瘤免疫
发表日期：2020
文献求助 收藏